July 26th 2024
A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
New insights expand available psoriasis treatments
August 15th 2019New psoriasis treatments are making their way to market. This supplement and the corresponding August issue take a broad look at the evolving understanding of the pathogenesis of psoriasis, the expanding treatment armamentarium, co-morbidity considerations, and financial considerations of new technologies.
Biologics make psoriasis clearance a real possibility
July 16th 2019“The landscape of biologics and biosimilars is changing rapidly, and for the better,” says Mark Lebwohl, M.D. Biologics have given patients the possibility of complete psoriasis clearance and control of their psoriatic arthritis (PsA), which were not options 20 years ago, adds Alice Gottlieb, M.D., Ph.D.
How to talk to psoriasis patients about their weight
July 11th 2019With the high incidence of psoriasis and psoriatic arthritis among patients who are obese, it’s important for dermatologists to address weight and weight management. But, having that conversation is not always easy. Dr. Soltani-Arabshahi offers tips to help you talk to your psoriasis patients about their weight.
Weight matters in psoriasis, psoriatic arthritis
July 11th 2019Data shows obesity is prevalent among patients with psoriasis and psoriatic arthritis, but the exact role weight plays in contributing to psoriatic disease and its severity is still unknown. At a minimum, industry experts agree that addressing obesity can be vital in treating psoriatic disease.
Racial disparities in psoriasis treatment
May 30th 2019A recent study explored why black individuals with psoriasis are disproportionately under treated. Authors compared differences in the perceptions and understanding of psoriasis therapies in both black and Caucasian patients. Here’s what they found.
Cardiovascular risk associated with psoriasis patient’s age, race
May 8th 2019Young African American patients with psoriasis are at a higher risk of atherosclerotic cardiovascular disease (ASCVD) and traditional cardiovascular risk factors than white patients with psoriasis of the same age group, says a recent study.
A patient-centered approach to psoriasis treatment
April 22nd 2019In psoriasis, many therapies offer roughly the same level of care, but that doesn’t mean any patient will respond well to any therapy. According to Mark Lebwohl, M.D., physicians should consider each treatment option in light of a patient's specific comorbidities.
Psoriasis research advances treatments for inflammatory skin diseases
April 15th 2019Continued psoriasis research has led to a translational revolution in inflammatory skin diseases. As a result, there are now a number of safer and more effective medications that can address a growing list of common immune-mediated skin diseases, such as atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa, acne, and rosacea.
JAK inhibitors offer multiple applications
March 21st 2019Unlike prior generations of dermatologic drugs, Janus kinase (JAK) inhibitors show potential for treating numerous dermatologic indications. Brett King, M.D., Ph.D. explored what this class of drug has to offer in his presentation during AAD earlier this month.
Utility of the methotrexate test dose
March 6th 2019Guidelines suggest that providing a small test dose of methotrexate to patients followed by laboratory evaluation can minimize the risk of serious adverse events associated with methotrexate. This small retrospective study examined whether methotrexate requires a test dose.
Can-Fite explores muscle tissue to fight psoriasis, cancer
March 6th 2019Chief executive officer of Can-Fite Biopharmaceuticals, Pnina Fishman, Ph.D. discovered why cancer and inflammation can go everywhere in the body, except muscle tissue. Using this knowledge, Can-Fite has developed a promising psoriasis drug, piclidenoson, which is currently in phase 3 clinical trials.